prikaz prve stranice dokumenta Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection
  Download
PDF 1.15 MB
Scientific paper - Original scientific paper
Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection
Journal of Clinical Medicine, 11 (2022), 22; 6695. https://doi.org/10.3390/jcm11226695
Krpina, Kristina; Mavrinac, Martina; Samaržija, Miroslav; Tolić, Ena; Darapi, Dora; Batičić, Lara

Cite this document

Krpina, K., Mavrinac, M., Samaržija, M., Tolić, E., Darapi, D. & Batičić, L. (2022). Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection. Journal of Clinical Medicine, 11. (22). doi: 10.3390/jcm11226695

Krpina, Kristina, et al. "Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection." Journal of Clinical Medicine, vol. 11, no. 22, 2022. https://doi.org/10.3390/jcm11226695

Krpina, Kristina, Martina Mavrinac, Miroslav Samaržija, Ena Tolić, Dora Darapi and Lara Batičić. "Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection." Journal of Clinical Medicine 11, no. 22 (2022). https://doi.org/10.3390/jcm11226695

Krpina, K., et al. (2022) 'Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection', Journal of Clinical Medicine, 11(22). doi: 10.3390/jcm11226695

Krpina K, Mavrinac M, Samaržija M, Tolić E, Darapi D, Batičić L. Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection. Journal of Clinical Medicine [Internet]. 2022 [cited 2024 December 06];11(22). doi: 10.3390/jcm11226695

K. Krpina, M. Mavrinac, M. Samaržija, E. Tolić, D. Darapi and L. Batičić, "Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection", Journal of Clinical Medicine, vol. 11, no. 22, 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:583604. [Accessed: 06 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection
AuthorKristina Krpina
AuthorMartina Mavrinac
AuthorMiroslav Samaržija
AuthorEna Tolić
AuthorDora Darapi
AuthorLara Batičić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Medical Informatics)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Chemistry and Biochemistry)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Intensive Care
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Infectology
Abstract (english)
Introduction: Lung cancer is one of the most diagnosed malignancies with increasing incidence worldwide. Immunotherapy is the main oncological treatment for advanced non-small cell lung cancer (NSCLC), for which the discovery of new efficient biomarkers is crucial. Scientific evidence points to the importance of the Lung Immune Prognostic Index (LIPI), but its predictive significance is unclear. Aim: The aim of this study was to investigate the clinical significance and predictive role of LIPI in patients with advanced NSCLC and PD-L1 mutation who are eligible for immunotherapy in combination with chemotherapy. In addition, to our knowledge, this is the first time that the association between COVID-19 infection and the course and outcome of oncologic treatment of NSCLC has been investigated. Patients and Methods: Patients were divided into four study groups according to strictly defined clinical parameters, therapeutic approach, and COVID-19 infection. LIPI was determined and its predictive power was evaluated in all studied groups, as well as overall survival (OS), progression-free survival (PFS), and disease control rate (DCR). Results: This study confirmed the understudied and uncertain predictive power and clinical relevance of LIPI as a biomarker in patients with advanced NSCLC. Patients infected with COVID-19 had a higher survival rate than uninfected patients despite the therapeutic approach, which may be attributed to their hospitalization and intensive medical management during the pandemic. Conclusions: Findings obtained in this study may help to determine treatment options according to the clinical condition of the patient by using LIPI values as a non-invasive, readily available and economically acceptable predictive biomarker in lung oncology.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleJournal of Clinical Medicine
Numberingvol. 11, no. 22, 6695
p-ISSN2077-0383
DOIhttps://doi.org/10.3390/jcm11226695
URN:NBNurn:nbn:hr:184:583604
Publication2022
Document URLhttp://bib.irb.hr/1233975
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-11-30 14:23:00